The trajectory of Viagra, initially marketed by copyright, presents a complex case study for backers considering the pharmaceutical arena . Although its initial success and generation of billions in earnings , the exclusivity end has opened the floodgates for competing medications, greatly eroding profit potential . This transition raises questions